➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
Boehringer Ingelheim
Medtronic
Baxter

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 8,268,566

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,268,566
Title:Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (\"TNFSF\")-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.
Inventor(s): Mitsuhashi; Masato (Irvine, CA), Endo; Katsuya (Ibaraki, JP), Obara; Kazuhiko (Ibaraki, JP), Izutsu; Hiroshi (Ibaraki, JP), Ohta; Shuji (Ibaraki, JP)
Assignee: Hitachi Chemical Research Center, Inc. (Irvine, CA) Hitachi Chemical Co., Ltd. (Shinjuku-ku, Tokyo, JP)
Application Number:12/743,220
Patent Claims:see list of patent claims

Details for Patent 8,268,566

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Hitachi Chemical Research Center, Inc. (Irvine, CA) Hitachi Chemical Co., Ltd. (Shinjuku-ku, Tokyo, JP) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Hitachi Chemical Research Center, Inc. (Irvine, CA) Hitachi Chemical Co., Ltd. (Shinjuku-ku, Tokyo, JP) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Hitachi Chemical Research Center, Inc. (Irvine, CA) Hitachi Chemical Co., Ltd. (Shinjuku-ku, Tokyo, JP) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
Medtronic
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.